About Idera

Idera Pharmaceuticals is a clinical stage biotechnology company involved in the discovery and development of compounds targeted to Toll-like Receptors (TLRs). The Company’s TLR-targeted candidates are being developed to treat autoimmune and inflammatory diseases, cancer, and for use as vaccine adjuvants.

Additionally, the Company is advancing its gene-silencing oligonucleotide (GSO) technology for the purpose of inhibiting the expression of disease-associated genes.

Therapeutic Areas

> CANCER

> AUTOIMMUNE DISEASES

> RESPIRATORY DISEASES

> HEMATOLOGIC ONCOLOGY

> VACCINE ADJUVANTS